Cited by 466Glioma Diagnosis and TreatmentLung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Haas-Kogan, Daphne A., Prados, Michael D., Tihan, Tarik, Eberhard, David A., Jelluma, Nannette, Arvold, Nils D., Baumber, Rachel, Lamborn, Kathleen R., Kapadia, Ami, Malec, Mary, Berger, Mitchel S., Stokoe, David·2005·JNCI Journal of the National Cancer Institute

DOI 10.1093/jnci/dji161

Open this paper in CoChat — free account

Abstract

BACKGROUND: The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib (also known as Tarceva or OSI-774) has shown promising response rates in malignant gliomas. We investigated the association between expression of EGFR and downstream signaling components and the response of malignant gliomas to erlotinib in a phase I trial of erlotinib administered either alone or with the alkylating agent temozolomide. METHODS: Expression of EGFR and ligand-independent EGFRvIII mutant proteins and of phosphorylated protein kinase B (PKB)/Akt in specimens from glioma patients were assessed by immunohistochemistry. EGFR gene amplification was evaluated by fluorescence in situ hybridization. Mutations in PTEN and EGFR were assessed by polymerase chain reaction amplification and sequencing. Response was evaluated by sequential magnetic resonance imaging every 2 months. The Cochran-Mantel-Haenzel test was used to assess associations between biomarker status and response. All statistical tests were two-sided. RESULTS: Of 41 glioma patients, eight responded to treatment. Response to erlotinib was associated with EGFR expression (P = .07) and EGFR amplification (P = .08). These associations were stronger and statistically significant among the 29 patients initially diagnosed with glioblastoma multiforme (P = .03 and P = .02, respectively). Among six responders with sufficient tumor tissue, none had EGFRvIII mutations. None of the 22 tumors with high levels of phosphorylated PKB/Akt responded to erlotinib treatment, whereas eight of the 18 tumors with low levels of phosphorylated PKB/Akt responded to erlotinib treatment (P < .001). The level of phosphorylated PKB/Akt was also associated with time to progression (P < .001). CONCLUSIONS: Among glioma patients, those with glioblastoma multiforme tumors who have high levels of EGFR expression and low levels of phosphorylated PKB/Akt had better response to erlotinib treatment than those with low levels of EGFR expression and high levels of phosphorylated PKB/Akt.

Integrity signals

Registry

Crossref · 10.1093/jnci/dji161

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,695
EGFR and cancer prognosis.
Nicholson, R., Gee, J., & Harper, M. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00231-3 · Cited by 2,132
Epidermal Growth Factor Receptor Gene and Protein and Gefitinib Sensitivity in Non–Small-Cell Lung Cancer
Cappuzzo, F., Hirsch, F. R., Rossi, E., Bartolini, S., Ceresoli, G. L., Bemis, L., Haney, J., Witta, S. E., Danenberg, K. D., Domenichini, I., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji112 · Cited by 1,538
Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer
Mendelsohn, J. M., & Baselga, J. M. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.504 · Cited by 1,257
ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization
Kallioniemi, O. P., Kallioniemi, A., Kurisu, W., Thor, A., Chen, L. C., Smith, H. S., Waldman, F. M., Pinkel, D., & Gray, J. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5321 · Cited by 555
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548

Show all 37 references

Research works printed but not linked: 2

Salz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc ASCO2001 (abstr); 20 : 7A .
Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO2002 (abstr); 21 : 504 .

Sorted by citations

Items 301–400 of 466

Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors
Leary, A. F., & Johnston, S. R. D. (2007) · Cancer Investigation · doi:10.1080/07357900701259694 · Cited by 16
Genomic and Epigenomic Features of Glioblastoma Multiforme and its Biomarkers
Jadoon, S. S., Ilyas, U., Zafar, H., Paiva‐Santos, A. C., Khan, S., Khan, S. A., Ahmed, T., Rasool, Y., Altaf, R., Raza, F., et al. (2022) · Journal of Oncology · doi:10.1155/2022/4022960 · Cited by 15
Novel Ion Channel Targets and Drug Delivery Tools for Controlling Glioblastoma Cell Invasiveness
Varricchio, A., Ramesh, S. A., & Yool, A. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111909 · Cited by 17
Tumours
Louis, D. N., Reifenberger, G., & Brat, D. J. (2008) · CRC Press eBooks · doi:10.1201/b13319-24 · Cited by 15
Using Genomics to Guide Treatment for Glioblastoma
Young, J. S., Prados, M. D., & Butowski, N. A. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0078 · Cited by 15
Origins and clinical relevance of proteoforms in pediatric malignancies
Lorentzian, A. C., Uzozie, A. C., & Lange, P. F. (2019) · Expert Review of Proteomics · doi:10.1080/14789450.2019.1575206 · Cited by 14
Molecular imaging and targeted therapies in oncology: New concepts in treatment response assessment. A collection of cases
Pantaleo, M. A. (1992) · International Journal of Oncology · doi:10.3892/ijo_00000026 · Cited by 14
Glioblastoma genetics: in rapid flux.
Purow, B. W., & Schiff, D. (2010) · PubMed · Cited by 14
PTEN in brain tumors
Haas-Kogan, D. A., & Stokoe, D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.4.599 · Cited by 14
Molecular biology of brain tumors
Li, J., Sulman, E. P., & Aldape, K. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00002-5 · Cited by 14
Molecular pathology of gliomas
Nupponen, N. N., & Joensuu, H. (2006) · Current Diagnostic Pathology · doi:10.1016/j.cdip.2006.06.007 · Cited by 14
Emerging therapies for malignant glioma
Lukas, R. V., Boire, A. A., & Nicholas, M. K. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.12s.s29 · Cited by 15
From Expert Review of Anticancer Therapy
Franceschi, E., Tosoni, A., Bartolini, S., Mazzocchi, V., Fioravanti, A., del Alba, A. G., & Brandes, A. A. (2010) · Cited by 15
Acridine Yellow G Blocks Glioblastoma Growth via Dual Inhibition of Epidermal Growth Factor Receptor and Protein Kinase C Kinases
Qi, Q., He, K., Yoo, M.-H., Chan, C. B., Liu, X., Zhang, Z., Olson, J. J., Xiao, G., Wang, L., Mao, H. Z., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.293605 · Cited by 13
Issues in Developing Drugs for Primary Brain Tumors: Barriers and Toxicities
Raizer, J. J. (2010) · Toxicologic Pathology · doi:10.1177/0192623310391482 · Cited by 13
Chemotherapy for malignant glioma
Nicholas, M. K., Lukas, R. V., & Bangalore, S. (2005) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.5.6.s41 · Cited by 13
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib
Kinsella, P., Howley, R., Doolan, P., Clarke, C., Madden, S. F., CLYNES, M. M., Farrell, M. A., & Murphy, V. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.01.014 · Cited by 13
mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside
Akhavan, D., & Mischel, P. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_5 · Cited by 13
Epidermal Growth Factor Receptor Inhibitors: A Moving Target?
Bates, S. E., & Fojo, T. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1845 · Cited by 13
Prognostic and Predictive Markers in Glioma and Other Neuroepithelial Tumors
Rivera, A. L., Pelloski, C. E., Sulman, E. P., & Aldape, K. D. (2008) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2008.02.003 · Cited by 12
Biomarkers of Clinical Responsiveness in Brain Tumor Patients
El-Jawahri, A. R., Patel, D., Zhang, M., Mladkova, N., & Chakravarti, A. (2008) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256285 · Cited by 12
Something Old and Something New About Molecular Diagnostics in Gliomas
Horbinski, C. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.09.001 · Cited by 13
Revoking the Privilege: Targeting HER2 in the Central Nervous System
Contessa, J. N., & Hamstra, D. A. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.042986 · Cited by 12
Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials
Hoosemans, L., Vooijs, M., & Hoeben, A. (2024) · Cancers · doi:10.3390/cancers16173021 · Cited by 13
Activation of EGFR Signaling from Pilocytic Astrocytomas to Glioblastomas
Carvalho, P. O., Uno, M., Oba‐Shinjo, S. M., Rosemberg, S., Wakamatsu, A., da Silva, C. C., Teixeira, M. J., & Marie, S. K. N. (2014) · The International Journal of Biological Markers · doi:10.5301/jbm.5000045 · Cited by 11
Innovative Therapies against Human Glioblastoma Multiforme
Cimini, A., & Ippoliti, R. (2011) · ISRN Oncology · doi:10.5402/2011/787490 · Cited by 11
Retracted
Current available therapies and future directions in the treatment of malignant gliomas
Vredenburgh, J. J. (2008) · Biologics · doi:10.2147/btt.2009.2727 · Cited by 10
Incorporating Molecular Tools into Early-Stage Clinical Trials
Weil, R. J. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050021 · Cited by 11
A novel lipoxygenase inhibitor Nordy attenuates malignant human glioma cell responses to chemotactic and growth stimulating factors
Chen, J., Yao, X., Gong, W., Hu, J., Zhou, X., Chen, K., Liu, H., Ping, Y., Wang, J. M., & Bian, X. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9369-4 · Cited by 11
Molecularly targeted therapy in neuro-oncology
Sathornsumetee, S., & Rich, J. N. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52138-5.00018-9 · Cited by 11
Incorporating molecular tools into clinical trials and treatment for gliomas?
Lassman, A. B., & Holland, E. C. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3282f1a05c · Cited by 11
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells
Berezowska, S. (2010) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000518 · Cited by 10
Molecular Tools: Biology, Prognosis, and Therapeutic Triage
Fischer, I., & Aldape, K. (2010) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2010.05.004 · Cited by 10
Connexin 43 C‐terminus directly inhibits the hyperphosphorylation of Akt/ ERK through protein–protein interactions in glioblastoma
Kuang, J., Guo, Y., Chen, Y., Wang, J., Duan, J., He, X., Li, L., Yu, S., & Bian, X. (2018) · Cancer Science · doi:10.1111/cas.13707 · Cited by 10
Enhancement of radiation sensitivity, delay of proliferative recovery after radiation and abrogation of MAPK (p44/42) signaling by imatinib in glioblastoma cells
Quick, Q., & Gewirtz, D. A. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.2.407 · Cited by 10
Insights into pharmacotherapy of malignant glioma in adults
Salvati, M., D’Elia, A., Formichella, A. I., & Frati, A. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903146910 · Cited by 9
Gliomagenesis: a game played by few players or a team effort?
Mazzoleni, S. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/370 · Cited by 9
Breast Cancer Patient with Li-Fraumeni Syndrome: A Case Report Highlighting the Importance of Multidisciplinary Management
Cirauqui, B., Morán, T., Estival, A., Quiroga, V., Etxániz, O., Balañá, C., Navarro, M., Villà, S., Ballester, R., & Vila, M. M. (2020) · Case Reports in Oncology · doi:10.1159/000505684 · Cited by 9
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models
Longo, S. L., Padalino, D. J., McGillis, S. L. B., Petersen, K., Schirok, H., Politz, O., Canute, G. W., & Post, D. E. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9784-4 · Cited by 9
Primary Brain Tumors: Characteristics, Practical Diagnostic and Treatment Approaches
Moore, K., & Kim, L. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_2 · Cited by 9
Novel molecular imaging platform for monitoring oncological kinases
Nyati, S., Ross, B. D., Rehemtulla, A., & Bhojani, M. S. (2010) · Cancer Cell International · doi:10.1186/1475-2867-10-23 · Cited by 9
Erlotinib prevents pulmonary metastasis in curatively resected breast carcinoma using a mouse model
Choi, Y., Nam, S. J., Son, M. J., Kim, D.-K., Kim, J. H., Yang, J., Kim, M., Song, H., Nam, D., & Bang, S. I. (2006) · Oncology Reports · doi:10.3892/or.16.1.119 · Cited by 9
Gliomas Biology: Angiogenesis and Invasion
Caffo, M., Barresi, V., Caruso, G., La, G., Angela, M., Raudino, G., Alafaci, C., & Tomasello, F. F. (2013) · InTech eBooks · doi:10.5772/53487 · Cited by 8
The Molecular Basis for Novel Therapies
Hu, J. L., & Kesari, S. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e3182455187 · Cited by 8
Novel Chemotherapeutic Approaches in Adult High-Grade Gliomas
Jordan, J. T., & Wen, P. Y. (2014) · Cancer treatment and research · doi:10.1007/978-3-319-12048-5_8 · Cited by 8
Correlative studies in neuro-oncology trials: Should they influence treatment?
Hegi, M. E., & Stupp, R. (2006) · Current Oncology Reports · doi:10.1007/s11912-006-0010-z · Cited by 8
Role of tyrosine kinase inhibitors in the management of high-grade gliomas
Ahluwalia, M. S., Patel, M. D., & Peereboom, D. M. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.166 · Cited by 7
An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study.
Wu, H., Muscato, N. E., González, A., & Shyr, Y. (2007) · PubMed Central · Cited by 7
Akt/protein kinase B overexpression as an accurate prognostic marker in adult diffuse astrocytoma
Matsutani, T., Nagai, Y., Mine, S., Murai, H., Saeki, N., & Iwadate, Y. (2009) · Acta Neurochirurgica · doi:10.1007/s00701-009-0199-3 · Cited by 7
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer
Altiok (2009) · International Journal of Oncology · doi:10.3892/ijo_00000471 · Cited by 12
Proteoforms: Methods of Analysis and Clinical Prospects
Kiseleva, O. I., Лисица, А. В., & Poverennaya, E. V. (2018) · Molecular Biology · doi:10.1134/s0026893318030068 · Cited by 6
Targeted therapy in the treatment of malignant gliomas
Nicholas, K. (2009) · OncoTargets and Therapy · doi:10.2147/ott.s3027 · Cited by 6
Overview of the Molecular Genetics and Molecular Chemotherapy of GBM
Newton, H. B. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0410-2_1 · Cited by 6
Evolution of care for patients with relapsed glioblastoma
Balañá, C., Villà, S., & Teixidor, P. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.152 · Cited by 6
Analysis of contribution of protein phosphorylation in the development of the diseases
Zavialova, M. G., Zgoda, V. G., & Николаев, Е. Н. (2017) · Biomeditsinskaya Khimiya · doi:10.18097/pbmc20176302101 · Cited by 6
Next generation sequencing and molecular imaging identify EGFR mutation and amplification in a glioblastoma multiforme patient treated with an EGFR inhibitor: a case report
Zhou, K., Yao, H., Zhang, X., Liu, J., Qi, Z., Xie, X., Xu, X., Zhou, Y., Yu, Z., Wang, Z., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18148 · Cited by 6
The PTEN/PI3 Kinase Pathway in Human Glioma
Stokoe, D., & Furnari, F. B. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_15 · Cited by 6
An EGFR and AKT Signaling Pathway was Identified with Mediation Model in Osteosarcomas Clinical Study
Wu, H., Muscato, N. E., González, A., & Shyr, Y. (2007) · Biomarker Insights · doi:10.1177/117727190700200035 · Cited by 6
Targeted therapy of glioblastomas: a 5-year view
Djedid, R., Robert Kiss, A., & Lefranc, F. (2009) · Therapy · doi:10.2217/thy.09.12 · Cited by 6
Diagnostic and prognostic molecular markers in common adult gliomas
Rivera, A. L., & Pelloski, C. E. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.44 · Cited by 6
Analysis of the role of protein phosphorylation in the development of diseases
Zavialova, M. G., Zgoda, V. G., & Николаев, Е. Н. (2017) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750817030118 · Cited by 5
Chemotherapeutic Agent for Glioma
Kohsaka, S., & Tanak, S. (2013) · InTech eBooks · doi:10.5772/54353 · Cited by 8
Research progress on criteria for discontinuation of EGFR inhibitor therapy
Zhuang, H., Lu-Jun, Zhiyong, Wang, J., Wang, W., & Zhang (2012) · OncoTargets and Therapy · doi:10.2147/ott.s36103 · Cited by 5
General and neurological complications of targeted therapy
Butowski, N. A., & Chang, S. M. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53502-3.00033-1 · Cited by 5
Gliomagenesis a game played by few players or a team effort
Galli, R. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e370 · Cited by 6
Recent advances in the treatment of central nervous system tumors
Liu, R., Chang, S. M., & Prados, M. D. (2008) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.11.002 · Cited by 5
Comparative genomic and proteomic analysis of high grade glioma primary cultures and matched tumor in situ
Howley, R., Kinsella, P., Buckley, P. G., Alcock, L., Jansen, M., Heffernan, J. M., Stallings, R. L., Brett, F. M., Murphy, V., & Farrell, M. A. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.06.007 · Cited by 6
Cytotoxic and molecular chemotherapy for high-grade glioma: an emerging strategy for the future
Cavaliere, R., & Newton, H. B. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.749 · Cited by 5
Co-occurrence of MGMT gene promoter methylation and amplification of EGFR in glioblastoma
Adamek, D., Zazula, M., Radwańska, E., Grzywna, E., Sińczak-Kuta, A., & Moskała, M. M. (2011) · Współczesna Onkologia · doi:10.5114/wo.2011.26436 · Cited by 4
Glioblastoma multiforme
Welch, M. R., & Lai, R. (2009) · Current Treatment Options in Neurology · doi:10.1007/s11940-009-0033-5 · Cited by 4
The Nf1–/+; Trp53–/+cis Mouse Model of Anaplastic Astrocytoma and Secondary Glioblastoma: Dissecting Genetic Susceptibility to Brain Cancer
Reilly, K. M. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_6 · Cited by 4
Central Nervous System Tumors
Aloisi, P., Martella, F., Cerone, D., & Porzio, G. (2012) · Humana Press eBooks · doi:10.1007/978-1-61779-615-9_1 · Cited by 4
Management of gliomas: relevance of molecular markers for clinical practice
Weller, M. (2012) · Journal für Kardiologie (Krause & Pachernegg GmbH) · doi:10.5167/uzh-85407 · Cited by 4
Chemical genetic approaches to the development of cancer therapeutics
Fan, Q.-W., & Weiss, W. A. (2005) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2005.12.002 · Cited by 4
Analysis of IDH and EGFR as biomarkers in glioblastoma multiforme: A case-control study
Al-Khatib, S., Al-Bzour, A. N., Almajali, M. N., Jarrad, T. A., AL-Eitan, L. N., & Abdo, N. M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35323 · Cited by 4
EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR FOR ONCOLOGY: DISCOVERY AND DEVELOPMENT OF ERLOTINIB
Iwata, K. K., Beard, S. E., & Haley, J. D. (2007) · Elsevier eBooks · doi:10.1016/b978-012369393-8/50010-9 · Cited by 3
Genetics and Biology of Glioblastoma Multiforme
do Carmo, A., Crespo, I., & Celeste, M. G. (2011) · InTech eBooks · doi:10.5772/23479 · Cited by 3
New molecular targets and novel anticancer treatments: emerging trends in neuro-oncology
Brandes, A. A., & Franceschi, E. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.8.1129 · Cited by 3
Synergistic Antitumor Effect between Gefitinib and Fractionated Irradiation in Anaplastic Oligodendrogliomas Cannot Be Predicted by the Egfr Signaling Activity
Pinel, S., Mriouah, J., Vandamme, M., Chateau, A., Plénat, F., Guérin, É., Taillandier, L., Bernier, V., Merlin, J., & Chastagner, P. B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0068333 · Cited by 3
Specific biomarkers of receptors, pathways of inhibition and targeted therapies: pre-clinical developments
Waerzeggers, Y., Monfared, P., Viel, T., Faust, A., Kopka, K., Schäfers, M. A., Tavitian, B., Winkeler, A., & Jacobs, A. H. (2011) · British Journal of Radiology · doi:10.1259/bjr/66405626 · Cited by 3
Angiogenesis in neurological disorders: a review
Acar, G., Tanrιöver, G., & Demir, R. (2012) · Neurological Research · doi:10.1179/1743132812y.0000000068 · Cited by 3
The infrequent simultaneous genetic alterations in glioblastoma multiforme (LOH 10, 17, 19q, TP53 mutation and EGFR amplification) with short clinical course.
Jesionek‐Kupnicka, D., Kulczycka-Wojdala, D., Rieske, P., Szybka, M., Jabłońska, J., Potemski, P., Kolasa, P., Liberski, P. P., & Kordek, R. (2007) · PubMed · Cited by 3
Management of Patients with High-Grade Glioma
Yuksel, S., Kolb, A., Solaroğlu, İ., & Watts, C. (2014) · EMJ Oncology · doi:10.33590/emjoncol/10312293 · Cited by 3
Unraveling the complexity of glioblastoma microenvironment: A comparative study of 3D and 2D cultures in response to combination drug therapy
Rashidi, R., Hadjighassem, M., & Negahdari, B. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149783 · Cited by 2
Novel therapies for high-grade gliomas: A vision for future
Tandon, V., Mahapatra, S., & Mahapatra, A. K. (2012) · Indian Journal of Neurosurgery · doi:10.4103/2277-9167.94372 · Cited by 2
Molecular Pathogenesis
Colman, H., & Aldape, K. D. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-166-0_2 · Cited by 2
Aberrant EGFR Signaling in Glioma
Hwang, Y., Latha, K., Gururaj, A. E., Rojas, M. L., & Bögler, O. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-553-8_20 · Cited by 2
Glioblastoma—more questions than answers?
Reardon, D. A. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0423 · Cited by 2
Contribution of Ectodomain Mutations in Epidermal Growth Factor Receptor to Signaling in Glioblastoma Multiforme
Rojas, M. L. (2011) · Digital Commons-TMC (Texas Medical Center) · Cited by 2
Tyrosine Kinase Inhibitors
Matthews, D. J., & Gerritsen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470555293.ch8 · Cited by 2
Reducing expression of dynamin-related protein 1 increases radiation sensitivity of glioblastoma cellsPreprint
Cheng, W.-Y., Chow, K., Chiao, M., Yang, Y., & Shen, C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/688861 · Cited by 2
Advances in Molecular Therapeutic Approaches to Patients with Malignant Gliomas
Newton, H. B. (2007) · Current Signal Transduction Therapy · doi:10.2174/157436207779317119 · Cited by 1
The evolution of chemotherapy in brain tumors: from historical milestones to precision medicine in glioblastoma
Ciafarone, A., & Palumbo, P. (2026) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2026.1002374 · Cited by 2
Chemo- and Radiosensitization Through Inhibition of PI3K/Akt Signaling
Smith, D. L., Nolden, L. K., Mills, G. B., & Lu, Y. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-221-2_17 · Cited by 1
Analysis of Binding Residues between PDGF-BB and Epidermal Growth Factor Receptor: A Computational Docking Study
Cabezas, R., Torrente, D., Ávila-Rodriguez, M., González, J., & Barreto, G. E. (2013) · Advances in intelligent systems and computing · doi:10.1007/978-3-319-01568-2_5 · Cited by 1
Biologie moléculaire des gliomes de l’adulte : quelques repères pour le neurochirurgien
Wager, M., Fontaine, D., & Karayan, L. (2008) · Neurochirurgie · doi:10.1016/j.neuchi.2008.04.002 · Cited by 1
New therapies for recurrent glioblastomas
Wen, P. Y. (2009) · F1000 Medicine Reports · doi:10.3410/m1-94 · Cited by 1
Treatment of High-Grade Gliomas in Adults
Drappatz, J., Norden, A. D., & Wen, P. Y. (2009) · Springer eBooks · doi:10.1007/978-3-642-00475-9_16 · Cited by 1
Glioblastoma Cancer Stem Cells: Response to Epidermal Growth Factor Receptor Kinase Inhibitors
Barbieri, F., Bajetto, A., Pattarozzi, A., Gatti, M., Würth, R., Porcile, C., Daga, A., Favoni, R. E., Corte, G., & Florio, T. (2011) · Springer eBooks · doi:10.1007/978-94-007-0344-5_22 · Cited by 1
Targeting EGFR in Glioblastoma: Molecular Biology and Current Understanding
Sepúlveda-Sánchez, J. M., Zahonero, C., & Sánchez‐Gómez, P. (2017) · Current cancer research · doi:10.1007/978-3-319-56820-1_5 · Cited by 1

Authors: Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., Berger, M. S., & Stokoe, D.
Affiliations: University of California, San Francisco (US)
Corresponding author: Haas-Kogan, Daphne A.
ORCID: Haas-Kogan, Daphne A.
Prados, Michael D.
Jelluma, Nannette
Arvold, Nils D.
Baumber, Rachel
Berger, Mitchel S.
Stokoe, David
Venue: JNCI Journal of the National Cancer Institute
Publisher: Oxford University Press (OUP)
Published: 2005-06-15
Volume: 97
Issue: 12
Pages: 880-887
ISSN: 0027-8874 (ISSN-L)
1460-2105
DOI: 10.1093/jnci/dji161
OpenAlex: W2104743043
Cited by: 465
References: 37
Citations by year: 2026: 3 · 2025: 2 · 2024: 4 · 2023: 8 · 2022: 4 · 2021: 4 · 2020: 9 · 2019: 5 · 2018: 7 · 2017: 13 · 2016: 6 · 2015: 17 · 2014: 24 · 2013: 27 · 2012: 34
FWCI: 22.18
Type: journal article
Language: en
Open access: closed
Locations: JNCI Journal of the National Cancer Institute (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5m01rr000079-42)
National Cancer Institute (P50CA097257)
National Institute of Neurological Disorders and Stroke (P01NS042927, P01 NS42927)
National Center for Research Resources (M01 RR-00079)
Topics: Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: erlotinib, EGFR tyrosine kinase inhibitors, high-grade glioma, glioblastoma, EGFR amplification, EGFRvIII, Akt phosphorylation, Akt, temozolomide, predictive biomarkers, treatment response, PTEN mutation, time to progression
MeSH terms: Erlotinib Hydrochloride, Temozolomide, Adult, Aged, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Dacarbazine, Drug Administration Schedule, Female, Glioma, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Phosphoric Monoester Hydrolases, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Supratentorial Neoplasms, Protein Serine-Threonine Kinases, In Situ Hybridization, Fluorescence, Drug Resistance, Neoplasm, Area Under Curve, Tumor Suppressor Proteins, Proto-Oncogene Proteins c-akt, PTEN Phosphohydrolase, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidermal Growth Factor Receptor, Protein Kinase B/Akt, and Glioma Response to Erlotinib

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks